AmpliPhi’s product development pathway
- Phase 1/2
- Phase 3
- Human therapeutic
- Pseudomonas aeruginosa is implicated in s. AmpliPhi has identified a large number of bacteriophages to target these infections.
- Staphylococcus aureus (especially the resistant form) is for many the definitive 'superbug.' AmpliPhi has identified a large number of bacteriophages to target this infection. A therapeutic mixture is in preparation.
- Acinetobacter baumannii is an increasing problem around the world and shows alarmingly high levels of antibiotic resistance. AmpliPhi scientists have identified a range of bacteriophages active against this infection.
- Clostridium difficile causes damaging infections, especially where normal bacteria have been disrupted by antibiotics. AmpliPhi is working to develop a bacteriophage therapeutic that will only target C.difficile, avoiding such effects.
- Veterinary therapeutic
- Pseudomonas aeruginosa is a major cause of , and AmpliPhi’s work in this area has identified a novel mixture of bacteriophages, which is now being prepared for initial veterinary trials.
- Use of antibiotics to combat Staphylococcus aureus infection of the bovine udder leads to high levels of antibiotics in the environment. A therapeutic bacteriophage mixture has been identified by AmpliPhi.
AmpliPhi Biosciences is the first company to demonstrate the clinical efficacy of phage technology in a controlled, regulated, human clinical trial. The Company’s leading bacteriophage therapeutic programs target areas of significant unmet clinical need, and its proprietary technology has additional applications for the treatment of a broad range of serious infections.
Scroll over bars to the left for information.